Trellis Bioscience: A Detailed Company Write-Up
Trellis Bioscience is a clinical-stage biotechnology company based in the United States, specializing in the discovery and development of native human monoclonal antibodies (mAbs) for the treatment and prevention of drug-resistant, life-threatening infectious diseases and cancer. The company???s core strategy centers on leveraging the natural power of the human immune system by isolating rare, highly effective antibodies directly from healthy donors. This approach aims to produce therapeutics that are naturally optimized, highly potent, and de-risked for drug development due to their fully human origin.
Continue…Core Technology and Approach: CellSpot???
The foundation of Trellis Bioscience's drug discovery is its proprietary, patented CellSpot??? platform. This innovative technology is designed to overcome the historical technical obstacles that have hindered the full exploitation of the human antibody repertoire.
The CellSpot??? platform functions by isolating and cloning genes of extremely rare, fully-human therapeutic monoclonal antibodies directly from the memory B-cells found in the blood of individual human donors. The technology???s high-throughput and high-resolution capabilities allow scientists to identify and select "elite" antibodies that bind to highly conserved target epitopes with high affinity. By sourcing these therapeutics directly from the human immune system, Trellis aims to develop products with superior safety profiles due to negligible toxicity from off-target binding, a common challenge with non-native or laboratory-generated antibodies.
Products and Pipeline
Trellis Bioscience has established a diverse pipeline of therapeutic candidates across infectious disease and oncology, all derived using the CellSpot??? platform.
1. Infectious Disease Pipeline
The company's primary focus in the infectious disease space is on the growing global threat of antibiotic resistance, particularly through the development of therapeutics that address bacterial biofilms.
- TRL1068 (Lead Product)
- Mechanism of Action: TRL1068 is a high-affinity, broad-spectrum native human antibody that specifically targets and disrupts bacterial biofilm. Biofilm is a major physiological factor that promotes drug resistance in the majority of clinically relevant multi-drug-resistant bacteria, as it shields the bacteria from eradication by conventional antibiotics. TRL1068 is designed to serve as an adjunctive treatment to eliminate this protective layer and dramatically increase the effectiveness of existing antibiotics.
- Clinical Status & Indications: The antibody has achieved clinical proof-of-concept in reducing biofilm burden and is being developed for the treatment of chronic Prosthetic Joint Infection (PJI). Chronic PJI is a severe, difficult-to-treat condition that often necessitates complex, two-stage surgical removal and replacement of the infected prosthesis, a costly and invasive procedure. TRL1068 has received key designations from the U.S. Food and Drug Administration (FDA), including Fast Track, QIDP (Qualified Infectious Disease Product), and Orphan Drug designation for PJI and infective endocarditis.
- Potential Broad Use: Beyond PJI, TRL1068 is being investigated for its potential to treat numerous other bacterial infections, including bloodstream and lung infections.
- Viral Antibodies
- TRL345: A native human monoclonal antibody developed to combat Human Cytomegalovirus (HCMV). TRL345 is notable for binding to the most conserved, and therefore critical, region of the virus, a mechanism previously shown to require rare somatic mutations in the antibody.
- RSV and Influenza: Trellis has a pipeline of drug candidates targeting Respiratory Syncytial Virus (RSV) and a pan-influenza antibody cocktail. The company has a history in this area, having previously licensed an anti-RSV mAb and an influenza A and B program to other biotech and pharmaceutical partners.
2. Oncology Pipeline
Trellis has also applied its CellSpot??? platform to cancer, focusing on the discovery of therapeutic antibodies in the field of Immuno-Oncology (IO).
- Immune Checkpoint Modulators (ICMs): The company was among the first to successfully discover native human monoclonal antibodies targeting ICMs. This discovery extends the concept of immune surveillance, suggesting that these natural mAbs may offer a better balance between anti-tumor efficacy and safety compared to synthetic laboratory-generated mAbs.
- Targeted Antigens: Trellis has cloned antibodies binding to various immune checkpoint and tumor-associated antigens (TAA). Specific targets include TIM-3 (T-cell immunoglobulin and mucin domain 3), LAG-3 (Lymphocyte-activation gene 3), KIR (Killer cell immunoglobulin-like receptors), CEACAM (Carcino-Ebryonic Antigen), and B7-H3. The clinical development of these oncology mAbs is being assessed in partnership with other biotechnology companies.
Business Model
Trellis Bioscience operates as a biotechnology drug discovery and development company. Its services are the output of its platform, meaning it does not offer the CellSpot??? platform as a commercial service per se, but rather uses it for its own product pipeline development (Discovery, Preclinical Development, and Clinical Trials). The company is venture-funded and has secured grant funding from organizations like the National Institutes of Health (NIH) and CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), validating its focus on critical global health threats. Its business model involves advancing its proprietary drug candidates through clinical trials, often seeking strategic partnerships for late-stage development, manufacturing, and commercialization, as evidenced by its licensing history and current oncology partnerships.
